You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Details for New Drug Application (NDA): 021301

✉ Email this page to a colleague

« Back to Dashboard

NDA 021301 describes LEVOXYL, which is a drug marketed by King Pharms and is included in one NDA. It is available from one supplier. Additional details are available on the LEVOXYL profile page.

The generic ingredient in LEVOXYL is levothyroxine sodium. There are ten drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.

Summary for 021301

Tradename:	LEVOXYL
Applicant:	King Pharms
Ingredient:	levothyroxine sodium
Patents:	0

Pharmacology for NDA: 021301

Suppliers and Packaging for NDA: 021301

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301	NDA	Pfizer Laboratories Div Pfizer Inc	60793-850	60793-850-01	100 TABLET in 1 BOTTLE (60793-850-01)
LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301	NDA	Pfizer Laboratories Div Pfizer Inc	60793-850	60793-850-10	1000 TABLET in 1 BOTTLE (60793-850-10)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:	May 25, 2001	TE:	AB1,AB3	RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:	May 25, 2001	TE:	AB1,AB3	RLD:	Yes

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:	May 25, 2001	TE:	AB1,AB3	RLD:	Yes

Expired US Patents for NDA 021301

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-006	May 25, 2001	⤷ Sign Up	⤷ Sign Up
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-005	May 25, 2001	⤷ Sign Up	⤷ Sign Up
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-012	May 25, 2001	⤷ Sign Up	⤷ Sign Up
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-004	May 25, 2001	⤷ Sign Up	⤷ Sign Up
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-001	May 25, 2001	⤷ Sign Up	⤷ Sign Up
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-009	May 25, 2001	⤷ Sign Up	⤷ Sign Up
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-007	May 25, 2001	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.